Zacks Investment Research Lowers Cytori Therapeutics (CYTX) to Sell
Zacks Investment Research cut shares of Cytori Therapeutics (NASDAQ:CYTX) from a hold rating to a sell rating in a report issued on Tuesday.
According to Zacks, “Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company’s preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient’s own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. “
Other research analysts have also issued research reports about the stock. Maxim Group set a $5.00 price target on shares of Cytori Therapeutics and gave the company a buy rating in a research note on Thursday, October 19th. B. Riley restated a hold rating on shares of Cytori Therapeutics in a research report on Tuesday, November 7th. Finally, ValuEngine upgraded shares of Cytori Therapeutics from a strong sell rating to a sell rating in a research report on Friday, February 2nd.
In other Cytori Therapeutics news, major shareholder Ag Postfinance sold 236,155 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $0.34, for a total transaction of $80,292.70. Following the transaction, the insider now owns 5,311,451 shares in the company, valued at approximately $1,805,893.34. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Bank Sa Swissquote sold 100,000 shares of the stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $0.38, for a total transaction of $38,000.00. Following the transaction, the insider now owns 5,496,655 shares in the company, valued at approximately $2,088,728.90. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 408,785 shares of company stock worth $142,987. Company insiders own 1.90% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Perkins Capital Management Inc. boosted its position in shares of Cytori Therapeutics by 134.0% during the 4th quarter. Perkins Capital Management Inc. now owns 2,136,041 shares of the biotechnology company’s stock worth $644,000 after acquiring an additional 1,223,046 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Cytori Therapeutics by 81.9% during the 2nd quarter. Vanguard Group Inc. now owns 612,304 shares of the biotechnology company’s stock worth $674,000 after acquiring an additional 275,653 shares in the last quarter. Finally, Sabby Management LLC boosted its position in shares of Cytori Therapeutics by 28.0% during the 2nd quarter. Sabby Management LLC now owns 1,626,807 shares of the biotechnology company’s stock worth $1,789,000 after acquiring an additional 355,504 shares in the last quarter. Institutional investors and hedge funds own 10.82% of the company’s stock.
About Cytori Therapeutics
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.